 Los Gatos, Calif., Dec. 12, 2022 GLOBE NEWSWIRE Aridis Pharmaceuticals, Inc. NASDAQ: ARDS, a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested 4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of AR-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung ... The post Updated Aridis Pharmaceuticals Receives Equity Investment from the Cystic... 